CD55 and CD59 expression were also correlated with the protection of HER2-overexpressing breast cancer and uterine serous carcinoma cells from trastuzumab-induced complement dependent cytotoxicity (135, 136). The gene discussed is CD59; the disease is breast carcinoma.